Redefining the way we make and take vaccines.
Imagine a world where all vaccines were taken as a capsule – no needles, long-term thermal stability, reduced need for healthcare professionals, global efficacy.
Is a ‘plug-and-play’ oral delivery vaccine platform. It effectively delivers non-replicating viral vectors to the GI tract to eliciting effective immunity against infectious diseases but not the viral vector. Stabilitech is using OraPro™ to develop the world’s first oral Zika vaccine.
Stabilitech is now using OraPro™ to develop oral vaccines for ‘blockbuster’ indications, including OraPro-HSV-2 to address the Herpes Simplex Virus 2, which currently affects 400 million people. The herpes market will be worth $9bn in 2018.
More about OraPro™ & pipeline developments
Is the world’s first omni-valent influenza vaccine. It is capable of delivering 15 strains in a single dose whereas current products can only deliver 3 or 4.
By increasing the strains per dose, OmniFlu™ can reduce strain selection mismatches (which recently have been running as high as 50%) thereby increasing the immunity of patients and saving lives. It also reduces costs for vaccine manufacturers and healthcare systems.
OmniFlu™ represents a potential paradigm shift in the fight against influenza and a breakthrough in a market forecast to be worth $4.3bn by 2025.
More about OmniFlu™
Zoetis is building on a long-term relationship with Stabilitech, a pioneer in thermostable technologies that preserve the efficacy of medicines and vaccines against high and low temperature extremes.
Zoetis and Stabilitech entered a three-year collaboration which will explore the potential of the company’s technologies in biopharmaceuticals and vaccines for animals.
Vaccines and other large biomolecules that could be sterilized, transported and stored at room temperature without significant degradation have the potential to transform animal healthcare – especially in developing countries where access to refrigeration in rural areas is a challenge.
I am delighted to be able to inform you that we have entered into an option and license agreement with GSK to evaluate Stabilitech’s thermal stability platform technology.
As you know, the Stabilitech platform technology enables development of thermally stable vaccines and biopharmaceuticals.
Under the terms of the research collaboration, GSK has the option to take an exclusive license for use in a defined field. We are not able to disclose further terms of the collaboration.
This is the second project we have worked on with GSK and is further technical validation of our technology and a milestone in our commercialization strategy.